European biotech and life sciences VC firm Forbion Capital raised €1.35B ($1.5B) toward two funds.
€750M ($820M) is earmarked for its early-stage Fund VI, with the
remaining €600M ($657M) set aside for its late-stage focused Growth
Opportunities Fund II. Both funds closed at their respective hard caps.
- Fund VI and Growth Opportunities Fund II will back startups developing novel therapeutics.
- Forbion's portfolio includes notable biotech startups such as Pheon Therapeutics, Rectify Pharma, and Seamless Therapeutics.
- Growth
Opportunities Fund II's predecessor fund, which closed at €470M ($514M)
in June 2022, has backed BioInvent, Basel, and Noema Pharma.
- Dutch
pension funds PME and PMT, Loyola University of Chicago, the Scott
Trust Endowment, and Pictet Alternative Advisors joined as limited partners for the early-stage fund, with Eli Lilly Pantheon, PME, and PMT joining as LPs for the growth-stage fund.
- Forbion now has over €3B ($3.2B) in assets under management.
